Riskpilot← Back to searchSign inGet full accessFusion Med Advice AB
ABActiveOrg 5592312796Västergårds Vale 3Other education n.e.c. · NACE 8559Est. 20190 employees
Revenue 2024
SEK 273K
+284% vs 2023
EBITDA margin
30.5%
+704% vs 2023
Equity ratio
44.0%
Financial strength
Net profit 2024
SEK 61K
+461% vs 2023
| Revenue | SEK 273K | +284% |
| EBITDA | SEK 83K | +704% |
| Net profit | SEK 61K | +461% |
| Total assets | SEK 432K | +119% |
| Equity | SEK 190K | +47% |
| Employees | 0 | — |
Legal name
Fusion Med Advice AB
Org number
5592312796
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
11 december 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolagets verksamhet skall vara konsultverksamhet inom odontologi, träning, hälsa och ledarskap samt därmed förenlig verksamhet.
Address
Västergårds Vale 3
Email
gita.gale01@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 145 | 52 | 31 | 71 | 273 |
| Staff expenses | — | — | −4 | −18 | −68 |
| EBITDA | 102 | −1 | −11 | 10 | 83 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 102 | −1 | −11 | 10 | 83 |
| Net financials | — | — | 0 | 2 | 4 |
| Profit before tax | 102 | −1 | −11 | 12 | 87 |
| Tax | −22 | −0 | — | −1 | −26 |
| Net profit | 80 | −1 | −11 | 11 | 61 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 204 | 164 | 208 | 197 | 432 |
| Equity | 130 | 130 | 119 | 129 | 190 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 74 | 34 | 90 | 68 | 242 |
| Total debt | 74 | 34 | 90 | 68 | 242 |
EBITDA margin
30.5%
This company
15.8%
Market median
+93% vs market
20202024
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20202024
Return on equity
31.9%
This company
18.4%
Market median
+73% vs market
20202024
Net profit margin
22.2%
This company
8.1%
Market median
+174% vs market
20202024
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20202024
Debt / equity
1.27×
This company
0.62×
Market median
-105% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-12-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2024 | |
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Fusion Med Advice AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Axel Edsberger | Board of Directors | 0 companies |
| Gita Cecilia Gale | Chairman | 0 companies |
| Samuel Jesper André Gale | Board of Directors | 0 companies |
| James Dominic Gale | Deputy Board Member | 0 companies |